Assembly Biosciences, Inc. (ASMB)

36.60USD +1.30% (+0.47)

Over 1M: +37.2%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

30 35
7 Aug 12 Aug 17 Aug 20 Aug 25 Aug 28 Aug 2 Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 10.8M Q3 '25 — Operating Income: -10.9M Q3 '25 — Net Income: -9.2M Q4 '25 — Operating Income: 19.8M Q4 '25 — Net Income: 22.1M Q1 '26 — Revenue: 8.2M Q1 '26 — Operating Income: -11.4M Q1 '26 — Net Income: -9.1M Q2 '26 — Revenue: 13.4M Q2 '26 — Operating Income: -6.3M Q2 '26 — Net Income: -3.9M -7M 0 7M 14M 21M 28M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Income Net Income

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

2.2
OE margin -62.6%
Oper. margin -12.2%
Profit margin -0.058%
ROA -0.013%
ROE -0.014%
Accruals 11.6%
EBITDA margin -12.0%
FCF margin -53.3%
OCF margin -53.2%
ROCE -2.9%
Gross margin —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

4.3
EV/Sales 5.9×
EV/OE -9.4×
P/C 2.3×
P/B 2.4×
FCF yield -5.2%
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

3.0
RPO / sales 0.23×
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

10.0
Current ratio 45.9×
ND/EBITDA 0.75
Cash runway 8.3 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 14.0×
F-score 3.9 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

8.7
Sales CAGR 4Y +84.4%
Sales/sh Y/Y +35.7%
Shares change +86.8%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales Q/Q —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.